Treadwell emerges with two clinical cancer compounds, $27M seed from Tio

Cancer play Treadwell debuted Monday as Tio Bioventures’s first portfolio company with $27 million in seed funding and a pair of differentiated oral small molecules that are already in the clinic.

Founded last year, Tio intends to invest its $120 million first fund in three to five internally incubated companies, with a primary focus on first-in-class therapies discovered de novo or in-licensed. Via its Tio Discovery unit, co-founder Shane Burgess said the firm provides R&D services “from white board all the way to clinic” while shepherding the start-ups until they’re ready for independence...